Supernus Pharma Files Proxy Statement

TL;DR

Supernus Pharma dropped its proxy statement for the June 16th shareholder meeting. Governance & exec pay details inside.

AI Summary

Supernus Pharmaceuticals, Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting on June 16, 2025. The filing outlines the company's governance and executive compensation details, as is standard for a DEF 14A filing. No specific financial figures or proposals are detailed in the provided header information.

Why It Matters

This filing provides shareholders with crucial information regarding company governance and executive compensation, enabling informed voting decisions at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine proxy statement filing, not indicating any immediate financial or operational risks.

Key Players & Entities

• SUPERNUS PHARMACEUTICALS, INC. (company) — Registrant
• 0001104659-25-042531.txt (document) — Filing document name
• 20250430 (date) — Filing date
• 20250616 (date) — Annual meeting date

FAQ

From the Filing

0001104659-25-042531.txt : 20250430 0001104659-25-042531.hdr.sgml : 20250430 20250430161724 ACCESSION NUMBER: 0001104659-25-042531 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 22 CONFORMED PERIOD OF REPORT: 20250616 FILED AS OF DATE: 20250430 DATE AS OF CHANGE: 20250430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 25895606 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 DEF 14A 1 tm252405-2_def14a.htm DEF 14A tm252405-1_nonfiling - none - 8.6250411s ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT   ☒ FILED BY A PARTY OTHER THAN THE REGISTRANT   ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ​ ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ​ ☒ Definitive Proxy Statement ​ ☐ Definitive Additional Materials ​ ☐ Soliciting Material under §240.14a-12 ​ SUPERNUS PHARMACEUTICALS, INC. ​ ​ (Name of the Registrant as Specified In Its Charter)   ​ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ​ ☐ Fee paid previously with preliminary materials. ​ ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. ​ ​   SUPERNUS PHARMACEUTICALS, INC. 9715 Key West Avenue Rockville, MD 20850 (301) 838-2500 ​ NOTICE OF ANNUAL MEETING OF STOCKHOLDERS VIRTUAL MEETING ONLY TO BE HELD AT 10:00 A.M. EDT, ON JUNE 16, 2025 ​ To the Stockholders of Supernus Pharmaceuticals, Inc.: NOTICE IS HEREBY GIVEN THAT the 2025 Annual Meeting of the Stockholders of Supernus Pharmaceuticals, Inc., a Delaware corporation (Supernus), will be held on Friday, June 16, 2025, at 10:00 A.M. Eastern Daylight Time. The meeting will be held virtually by means of a live webcast and you will be able to attend the Annual Meeting online, vote your shares electronically and submit your questions prior to and during the meeting by visiting meetnow.global/MXGLRPM on the meeting date and at the time set forth above. There is no physical location for the Annual Meeting. Your attendance at the virtual Annual Meeting affords you the same rights and opportunities to participate as you would have at an in-person annual meeting. At the 2025 Annual Meeting of Stockholders, you will be asked to consider and vote upon the following matters: 1. to elect two (2) directors to hold office for the ensuing three (3) years and until their successors have been duly elected and qualified; ​ 2. to approve, on a non-binding basis, the compensation paid to our named executive officers; ​ 3. to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and ​ 4. to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof. ​ The Board of Directors has fixed the close of business on April 22, 2025, as the Record Date for the determination of holders of common stock of Supernus entitled to notice of, and to vote at, the